Short-term complications of intravitreal injections of triamcinolone and bevacizumab
Short-term complications of intravitreal injections of triamcinolone and bevacizumab
复制标题
DOI：
10.1038/eye.2008.10
复制
发表时间：
2008-04-01
期刊：
影响因子：
3.9
通讯作者：
Schlichtenbrede, F.
中科院分区：
文献类型：
--
作者：
Jonas, J. B.;Spandau, U. H.;Schlichtenbrede, F.
目的评价玻璃体腔注射贝伐单抗和曲安奈德后并发症的发生率。方法对5403例玻璃体腔注射曲安奈德20 mg的患者进行临床干预性病例系列研究（n = 1588）或1.5 mg贝伐珠单抗（n = 3818）在2000年至2007年期间由三名外科医生连续进行，用于治疗各种眼内水肿或新生血管性疾病。每次注射后随访至少4 weeks.Results感染性眼内炎，需要睫状体平坦部玻璃体切除术检测到两个眼睛（2/5403或0.04 +/- 0.03%）从贝伐单抗组。两只眼睛贝伐珠单抗组（2/5403或0.04 +/- 0.03%）显示无痛性玻璃体混浊，在强化局部抗生素治疗后消退; 1只眼（1/5403或0.02 ± 0.02%）发生视网膜脱离;三只眼睛（3/5403或0.06 +/-0.03%）（贝伐单抗组两只眼睛）显示出快速进行性白内障。这些并发症的总发生率为8/5403（0.15 +/- 0.05%）。从统计学上看，（P = 0.18），注射药物（P = 0.45），患者年龄结论玻璃体内注射贝伐单抗或曲安西龙后，注射相关并发症如感染性眼内炎、视网膜脱离和外伤性白内障的发生率约为0.15 ± 0.05%，与注射的药物无关。
Aims To evaluate the rate of complications after intravitreal injection of bevacizumab and triamcinolone.Methods The clinical interventional case-series study included 5403 intravitreal injections of about 20mg triamcinolone acetonide (n = 1588) or 1.5mg bevacizumab (n = 3818) consecutively performed in the period from 2000 to 2007 by three surgeons for treatment of various intraocular edematous or neovascular diseases. Follow-up after each injection was at least 4 weeks.Results An infectious endophthalmitis which necessitated pars plana vitrectomy was detected in two eyes (2/5403 or 0.04 +/- 0.03%) from the bevacizumab group. Two eyes (2/5403 or 0.04 +/- 0.03%) from the bevacizumab group showed a painless vitreous clouding which subsided after intensified topical antibiotic therapy; one eye (1/5403 or 0.02 +/- 0.02%) developed a retinal detachment; and three eyes (3/5403 or 0.06 +/- 0.03%) (two eyes from the bevacizumab group) showed a rapidly progressive cataract. The total rate of these complications was 8/5403 (0.15 +/- 0.05%). It was statistically independent of the surgeon (P = 0.18), the drug injected (P = 0.45), and the age of the patients (P = 0.87).Conclusions Injection-related complications such as infectious endophthalmitis, retinal detachment, and traumatic cataract may occur with a frequency of about 0.15 +/- 0.05% after intravitreal injections of bevacizumab or triamcinolone, independently of the drug injected.